Indianapolis, INNCT06663332Now EnrollingIRB Ready

Crohns Disease Clinical Trial in Indianapolis, IN

Access cutting-edge crohns disease treatment through this clinical trial at a research site in Indianapolis. Study-provided care at no cost to qualified participants.

Sponsored by Janssen Research & Development, LLC

Quick Self-Assessment

See if you qualify for this Indianapolis location

Preparing your pre-screening questions…

Expert Care in Indianapolis

Access crohns disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related crohns disease treatment provided free

Apply for This Indianapolis Location

Check if you qualify for this crohns disease clinical trial in Indianapolis, IN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Indianapolis

    Convenient for IN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Indianapolis site if eligible
  4. 4Begin participation

About This Crohns Disease Study in Indianapolis

The purpose of this study is to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative colitis, or moderately to severely active Crohn's disease, or juvenile psoriatic arthritis (jPsA).

Sponsor: Janssen Research & Development, LLC

Who Can Participate

Inclusion Criteria

Must have completed the dosing planned in the primary pediatric guselkumab study
Must have received benefit from continued guselkumab therapy in the opinion of the investigator
Before enrollment, a participant must be either: (a) Not of childbearing potential, OR (b) Of childbearing potential and not sexually active, practicing abstinence or a highly effective method of contraception and agrees to remain on a highly effective method while receiving study intervention and until 12 weeks after the last dose - the end of relevant systemic exposure
Parent(s) (or their legally acceptable representative) must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to allow the child to participate in the study. Assent is required from participants who are capable of understanding the nature of the study, typically those aged 7 years and older, to ensure their willingness to participate. An adolescent who provides assent will have the opportunity to sign an adult ICF upon reaching the age of majority, thereby affirming their understanding of the study's purpose and procedures, as well as their willingness to participate.

Exclusion Criteria

Participant is greater than or equal to (\>=) 18 years of age and resides in a country where 2 years have elapsed post marketing authorization for the respective adult indication
Participant is \<18 years of age and resides in a county where 2 years have elapsed post marketing authorization for the respective pediatric indication
Are pregnant, nursing, or planning pregnancy or fathering a child
Have taken any disallowed therapies before the planned first long-term extension (LTE) dose of study intervention
Employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator
Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Indianapolis?

Yes, this clinical trial (NCT06663332) has an active research site in Indianapolis, IN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Crohns Disease Treatment Options in Indianapolis, IN

If you're searching for crohns disease treatment options in Indianapolis, IN, this clinical trial (NCT06663332) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Indianapolis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced crohns disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all crohns disease clinical trials near you to find additional studies recruiting in your area.

More Crohns Disease Trials in Indianapolis, IN

See all crohns disease clinical trials recruiting in Indianapolis — not just this study.

Browse Crohns Disease Trials in Indianapolis →

Browse More Trials by Condition

Crohns Disease TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Indianapolis?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Indianapolis, IN